Tiziana Therapeutics initiated at Laidlaw

Tiziana Therapeutics initiated with a Buy at Laidlaw. Laidlaw analyst Francois Brisebois initiated Tiziana Therapeutics with a Buy and $17 price target saying the main value driver consists of Foralumab in development as a potential treatment for large unmet medical needs such as NASH. While Foralumab remains in Phase 1, Brisebois sees their fully human oral anti-CD3 mAb as relatively de-risked as fully murine OKT3 showed encouraging immunological trends in a previous Phase 2 trial in NASH. The analyst said 2019 is setting up as a catalyst year with potential data readouts in both their oral and intranasal Foralumab trials as well as their Phase 2a monotherapy.
https://thefly.com/landingPageNews.php?id=2837835